Technetium-99m tetrofosmin imaging in thyroid diseases: Comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans

被引:33
作者
Klain, M
Maurea, S
Cuocolo, A
Colao, A
Marzano, L
Lombardi, G
Salvatore, M
机构
[1] UNIV NAPLES FEDERICO II,CNR,CTR STUDIO MED NUCL,NAPLES,ITALY
[2] IST NAZL TUMORI,NAPLES,ITALY
来源
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1996年 / 23卷 / 12期
关键词
technetium-99m labelling; tumour-seeking agents; thyroid imaging; tetrofosmin; thallium-201; methoxyisobutylisonitrile;
D O I
10.1007/BF01249618
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Technetium-99m tetrofosmin is a lipophilic phosphine used for myocardial perfusion imaging. Biodistribution studies have shown significant thyroid uptake of tetrofosmin and preliminary reports have suggested that tetrofosmin imaging may be of value in patients with thyroid cancer. In this study, tetrofosmin whole-body scintigraphy was performed in 35 patients with evidence of thyroid diseases. All patients underwent laboratory evaluation of thyroid function as well as Tc-99m pertechnetate scan, thallium-201 (n=16) Tc-99m-methoxyisobutylisonitrile (MIBI) (n=19) whole-body studies. Thyroid images were semi-quantitatively analysed by a 4-point score: 0=no significant uptake; 1=uptake increased as compared to background activity, but inferior to normal thyroid tissue; 2=uptake equal to normal thyroid tissue; 3=uptake superior to normal thyroid tissue, Pathology examinations were obtained. A total of 41 thyroid nodules were detected, of which 15 were goitre nodules, 13 adenomas and 13 malignant lesions, In goitre nodules, concordant results of tetrofosmin and pertechnetate uptake (score 1 or 0) were observed in the majority of lesions (87%). In function adenomas (n=10), both tetrofosmin uptake and pertechnetate uptake were score 3. In non-function adenomas (n=3), tetrofosmin uptake was score 3, while pertechnetate uptake was score 0, In six malignant lesions, tetrofosmin uptake was score 3, while pertechnetate uptake was score 0; in the other seven lesions, where a prevalence of goitre abnormalities was observed, results of tetrofosmin and pertechnetate uptake were similar (score 0 or 1). In seven (70%) of the ten patients with malignant nodules, whole-body tetrofosmin images showed increased abnormal uptake in a total of 28 extra-thyroid tumour sites, as subsequently confirmed by other techniques. When tetrofosmin images were compared to Tl-201 and Tc-99m-MIBI scans, concordant results were observed in all cases, In conclusion, tetrofosmin imaging may be particularly useful to characterize and stage patients with malignant thyroid nodules; it shows similar results to thallium but provides better image quality. Comparable findings were observed between tetrofosmin and MIBI studies, Thus, tetrofosmin may be an alternative to thallium and MIBI in the aforementioned patients.
引用
收藏
页码:1568 / 1574
页数:7
相关论文
共 30 条
  • [1] TECHNETIUM-99M-TETROFOSMIN UPTAKE IN MALIGNANT LUNG-TUMORS
    BASOGLU, T
    SAHIN, M
    COSKUN, C
    KOPARAN, A
    BERNAY, I
    ERKAN, L
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (07): : 687 - 689
  • [2] BEIERWALTES WH, 1991, J NUCL MED, V32, P1455
  • [3] CLARKE SEM, 1991, DIAGNOSTIC IMAGING, V30, P43
  • [4] CUOCOLO A, 1995, J NUCL MED, V36, P907
  • [5] CLINICAL UTILITY OF TC-99M METHOXISOBUTYLISONITRILE IMAGING IN DIFFERENTIATED THYROID-CARCINOMA - COMPARISON WITH THALLIUM-2O1 AND I-131 NA SCINTIGRAPHY, AND SERUM THYROGLOBULIN QUANTITATION
    DADPARVAR, S
    CHEVRES, A
    TULCHINSKY, M
    KRISHNABADRINATH, L
    KHAN, AS
    SLIZOFSKI, WJ
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (11): : 1330 - 1338
  • [6] EL-DESOUKI M, 1991, Clinical Nuclear Medicine, V16, P425, DOI 10.1097/00003072-199106000-00010
  • [7] HARDOFF R, 1991, J NUCL MED, V32, P1873
  • [8] HIGHLEY B, 1993, J NUCL MED, V34, P30
  • [9] TC-99M TETROFOSMIN - A NEW DIAGNOSTIC TRACER FOR PARATHYROID IMAGING
    ISHIBASHI, M
    NISHIDA, H
    KUMABE, T
    MORITA, S
    MATOBA, F
    NOMURA, G
    HAYABUCHI, N
    [J]. CLINICAL NUCLEAR MEDICINE, 1995, 20 (10) : 902 - 905
  • [10] Jones S., 1993, J NUCL MED TECHNOL, V21, P191